All results
1 results
-
ATB200-08
This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in…
- Ages
- N/A - 17 Years
- Sexes
- All